Dormant
TNDM · Tandem Diabetes Care, Inc.
Last analysed ·
Resolved Graded and closed 2026-08-07 at low conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-13 and is not part of the scored record.
Current thesis
Beaten-down insulin-pump turnaround; the whole re-rate hinges on the tubeless Mobi ("Toby") 510(k) — planned for a Q2 filing but still unconfirmed after the quarter closed 2026-06-30 — plus margins scaling toward a ~60% Q4 exit. Shares bounced off the floor to ~$17 but sell-side stays neutral (Mizuho cut to $20). The 2026-08-06 Q2 print is the next binary.
Kill line
A weekly close below $14 forfeits the July recovery base and re-opens the downtrend toward the $9.98 52-week floor. Secondary: the tubeless Mobi 510(k) still unconfirmed at the 2026-08-06 Q2 print, a FY2026 sales guide cut below $1.065B, or diabetes-AID leadership staying with Insulet's Omnipod.
Pick status
Played out resolved published kill line did not fire How this is scored →Latest analysis and events for TNDM —
As of 13 September 2026, the latest FrontierPicks analysis for Tandem Diabetes Care, Inc. (TNDM): 1 July 2026: launched t:slim X2 Control-IQ+ integration with Abbott FreeStyle Libre 3 Plus in UK, Switzerland, Sweden, Finland, Italy; more EU markets guided later 2026.
Kill line: A weekly close below $14 forfeits the July recovery base and re-opens the downtrend toward the $9.98 52-week floor. Secondary: the tubeless Mobi 510(k) still unconfirmed at the 2026-08-06 Q2 print, a FY2026 sales guide cut below $1.065B, or diabetes-AID leadership staying with Insulet's Omnipod.
Next dated event on file: — catalyst in 8d.
Current Thesis
Tandem Diabetes Care's recovery thesis rests on tubeless Mobi clearance and sustained margin improvement; confirmation requires clearance by 2026-12-31 and a weekly close above the 2026-08-28 reference close of $21.43 before a weekly close below $14. The regulatory application is already filed: Tandem's 2026-08-06 results confirmed submission to the U.S. Food and Drug Administration (FDA) during the second quarter. Tandem results
The change since the 2026-08-30 assessment is price deterioration. The supplied adjusted market close was $17.11 on 2026-09-11, below the previously cited $21.43 close on 2026-08-28. The narrative is maturing — the margin improvement was disclosed on 2026-08-06 and William Blair initiated coverage on 2026-08-21, but September's price evidence does not establish renewed participation. This is an inference about the recovery story, with low conviction until the published confirmation conditions occur.
Bullish and bearish views on Tandem Diabetes Care, Inc.
The model's bull view on Tandem Diabetes Care, Inc. (TNDM), in brief: Margins have already improved. Tandem reported second-quarter 2026 gross margin of 57%, versus 52% a year earlier, on 2026-08-06. This supports the operating turnaround independently of future product clearance. Tandem results Pharmacy distribution has measurable adoption. The… The bear view: Revenue guidance did not rise. Tandem reaffirmed 2026 sales guidance of $1.065–1.085 billion on 2026-08-06. A reduction below the range's lower bound would contradict the revenue premise supporting the recovery. Tandem results Borrowings exceed reported cash. The 2026-06-30… Both cases follow in full.
Bull Case
- Margins have already improved. Tandem reported second-quarter 2026 gross margin of 57%, versus 52% a year earlier, on 2026-08-06. This supports the operating turnaround independently of future product clearance. Tandem results
- Pharmacy distribution has measurable adoption. The 2026-08-06 release reported that pharmacy accounted for 10% of second-quarter U.S. sales. Channel conversion therefore has an observable revenue contribution. Tandem results
- Coverage supports the product thesis. William Blair's Steven Lichtman initiated Outperform on 2026-08-21, citing tubeless Mobi and pharmacy distribution, according to Benzinga's initiation report. That is an attributed analyst view; the application alone does not establish clearance or commercial adoption.
Bear Case
- Revenue guidance did not rise. Tandem reaffirmed 2026 sales guidance of $1.065–1.085 billion on 2026-08-06. A reduction below the range's lower bound would contradict the revenue premise supporting the recovery. Tandem results
- Borrowings exceed reported cash. The 2026-06-30 balance sheet reported $602.6 million of convertible senior notes and $456.0 million of cash and equivalents. Those figures establish financing exposure, without establishing that an issuance is imminent. Tandem results and balance sheet
- The market recovery has weakened. On 2026-09-11, the supplied price series placed TNDM 39.5% below its 52-week high, despite a three-month price increase of 3.1%. Neither measure establishes that a durable recovery base has formed.
Setup & Price Structure
The 2026-09-11 adjusted close of $17.11 is the current market reference. The 14-period relative strength index (RSI) was 9.9 on that date. This measures weak recent momentum; it does not establish the probability or timing of a rebound.
The $14 weekly-close threshold remains the research invalidation carried in the 2026-08-30 public assessment. It is a defined thesis boundary, not a newly verified support level. A weekly close above $21.43, the reference close cited for 2026-08-28, would satisfy the price component of confirmation; regulatory clearance must also occur by 2026-12-31.
Positioning evidence remains limited. Benzinga reported Citi's Neutral rating and $21 analyst target on 2026-08-07, followed by William Blair's Outperform initiation on 2026-08-21. These observations document analyst attention, but the available evidence does not provide a dated short-interest series, fund-flow measure or representative retail-sentiment sample. No conclusion about crowding follows from those coverage items alone.
Catalyst Calendar (next 30 days)
- 2026-09-28 through 2026-10-02: The European Association for the Study of Diabetes (EASD) annual meeting takes place in Milan. Its industry programme schedules Sanofi-Dexcom and Abbott sessions on 2026-09-28; this is a sector information event, with no confirmed Tandem-specific clearance announcement. Meeting dates, industry programme
- 2026-09-29: Abbott's programme includes a session on dual sensing. It provides context for diabetes-device development, but the programme does not establish a Tandem product integration or revenue contribution. Industry programme
As checked on 2026-09-13, Tandem's investor calendar lists no upcoming presentation. No company-confirmed earnings date or FDA decision date is established for the window ending 2026-10-13. Tandem events
The later thesis checkpoint is 2026-12-31, the end of the late-2026 product window cited in William Blair's 2026-08-21 initiation. This is a research deadline, not a scheduled FDA decision. Absence of clearance by that date invalidates the timing component.
What Would Change Our Mind
Failure of the recovery structure is defined by a weekly close below $14, the threshold published in the 2026-08-30 assessment. That condition ends the price thesis even if the regulatory application remains under review.
The operating case would break if Tandem reduced its 2026 sales outlook below $1.065 billion or its gross-margin outlook below the 56–57% range reaffirmed on 2026-08-06. Clearance by 2026-12-31, intact guidance and a weekly close above the 2026-08-28 reference close of $21.43 would establish the stated recovery case. Tandem guidance
Correlation Notes
This remains a single-company turnaround assessment. The 2026-09-28 EASD programme places Dexcom and Abbott in the same diabetes-technology information window, establishing shared event exposure rather than measured stock-price correlation. Industry programme
The supplied 2026-09-11 observations contain no matched peer-return series. The sample is too small to support a correlation claim or to attribute TNDM's weakness to a broader diabetes-device move.
Notes
- 2026-07-01: launched t:slim X2 Control-IQ+ integration with Abbott FreeStyle Libre 3 Plus in UK, Switzerland, Sweden, Finland, Italy; more EU markets guided later 2026.
- Capital structure: $602.6M of convertible senior notes against $456.0M cash and equivalents at 2026-06-30 — a standing refinancing and dilution consideration.
- GAAP and adjusted results diverge materially: Q2 2026 net loss $21.2M alongside positive adjusted EBITDA of $6.4M; FY2026 stock-based comp guided near $65M.
- The Mobi tubeless 510(k) has no publicly scheduled FDA decision date; 510(k) reviews are not pre-announced the way PDUFA dates are.
- International is roughly a third of guided FY2026 sales ($335-340M of $1.065-1.085B), carrying FX and country-level reimbursement exposure.
- Competitive set is entrenched: Insulet Omnipod 5 in patch pumps, Beta Bionics (Dexcom-paired), and a planned Medtronic MiniMed patch.
- William Blair does not publish price targets with its ratings, so its 2026-08-21 Outperform adds a rating but no level to the consensus.
Related · shared themes
TXG
10x Genomics, Inc.
10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a weekly close below $58.57 invalidates the structure.
ITGR
Integer Holdings Corporation
Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
VREX
Varex Imaging Corporation
Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it.
See also · stocks to watch